Synthetic Biology
Engineering cells to make new products
Thesis
Synthetic biology's promise — programming cells like software — is finally hitting commercial reality, but the gap between demo and scale is where most companies die. Ginkgo proved the platform model can reach public markets; it hasn't yet proved it can reach profitability. The real question is whether foundry economics work at scale, or whether synbio is a services business pretending to be a product one.
The winners will own the design-build-test-learn loop end to end. That means vertically integrated companies with proprietary strain libraries, automated fermentation, and — critically — downstream partnerships that pull product through to market. Zymergen's implosion taught the field that biology risk doesn't disappear just because you have good software. The next generation knows this: Ginkgo, Amyris's successors, and a crop of stealth startups are building with capital efficiency baked in.
Watch: who can get a novel molecule from engineered organism to commercial sale in under 36 months. That's the threshold. Everything slower than that is a science project with a pitch deck.
Last updated 2026-03-15
Featured Models
UW Baker Lab
Protein Design, De Novo Generation, Binder Design
UW Baker Lab
Sequence Design, Inverse Folding
Arc Institute
DNA Language Model, Genome Generation, Regulatory Element Prediction
Companies
Ginkgo Bioworks
The organism engineering company.
The most important synbio company and also the most confusing. Ginkgo proved the platform model can reach public markets but hasn't proved it can reach profitability. Their biosecurity pivot is smart diversification. Watch the margin trajectory.
Arzeda
Computational protein design for industrial biology.
One of the few synbio companies that's actually shipping designed enzymes to paying customers. Revenue from real products, not just platform deals. The Baker Lab lineage gives them a structural biology edge most competitors lack.
Absci
Generative AI drug and target discovery.
Positioned at the intersection of synbio and AI drug discovery. Their generative antibody platform is genuinely novel, but being public and pre-revenue in this market is brutal. The AstraZeneca partnership is the lifeline — if it produces a clinical candidate, everything changes.
Funding
Arzeda
Series B · 2024-12-03
Led by Lux Capital, Prelude Ventures
Computational enzyme design is one of those fields where the science has been 20 years ahead of the business model. Arzeda is finally closing that gap with real industrial customers. The David Baker lineage gives them credibility, and the enzyme market is enormous if you can actually deliver on de novo design at commercial scale.
Ginkgo
PIPE · 2024-06-14
Led by Baillie Gifford, ARK Invest
Ginkgo is the AWS of biology — nobody questions the vision, everyone questions the unit economics. The platform-as-a-service model works beautifully in slide decks, but downstream royalties take years to materialize. This PIPE buys them runway, but the clock is ticking on proving that foundry economics actually scale.
Signals
David Baker, Alexandre Zanghellini, Daniela Grabs et al. · 2025-02-18
If this result holds up, it is the most consequential paper in applied protein engineering in a decade. Directed evolution is the gold standard — showing that zero-shot computational design can match it eliminates the biggest bottleneck in industrial biotech. The caveat: these are all well-characterized reaction types. Novel chemistry remains an open problem.
Phase I Evaluation of AZD-ENZ-104, a De Novo Designed Enzyme Replacement Therapy for Phenylketonuria
Arzeda Corporation · Phase I · Active, not recruiting
A computationally designed enzyme that never existed in nature, now going into humans. This is the moment David Baker has been building toward for two decades. PKU is the right proof-of-concept — monogenic, clear endpoint, desperate patient population. If the immunogenicity is manageable, this opens the floodgates for de novo enzyme therapeutics.
Phase I Study of a Synthetically Optimized mRNA Vaccine Candidate for Seasonal Influenza
Ginkgo Bioworks / Pfizer · Phase I · Recruiting
Jason Kelly, Reshma Shetty, Patrick Boyle et al. · 2024-07-22
Ginkgo is publishing its way to relevance in cell therapy. The synthetic promoter library is genuinely massive — 500K variants screened in primary human T cells. But the real play is locking pharma partners into the Ginkgo codebase. Once your cell therapy program depends on their proprietary regulatory elements, switching costs become enormous. This is a platform paper disguised as a science paper.